Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Steven A. Barker
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1749-1763
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
Ayahuasca‐enhanced extinction of fear behaviour: Role of infralimbic cortex 5‐HT2A and 5‐HT1A receptors
Isabel Werle, Laura Maria Martins Nascimento, A. Santos, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 11, pp. 1671-1689
Closed Access | Times Cited: 14
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk
Dan Cheng, Zhuogui Lei, Kin Chu, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 14
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 33-46
Closed Access | Times Cited: 1
Exploring DMT: Endogenous Role and Therapeutic Potential
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access | Times Cited: 1
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
Andreas Halman, Geraldine Kong, Jerome Sarris, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 17
Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
Klemens Egger, Helena D. Aicher, Paul Cumming, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 6
New Paradigms of Old Psychedelics in Schizophrenia
Danish Mahmood, Sattam Khulaif Alenezi, Md Jamir Anwar, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 640-640
Open Access | Times Cited: 25
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e112-e120
Closed Access | Times Cited: 5
Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine
Dario A. Dornbierer, Laurenz Marten, Jovin Mueller, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial
Marcus Mueller, Helena D. Aicher, Dario A. Dornbierer, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data
Steven A. Barker
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111259-111259
Closed Access
Tryptamine based drugs
Shaun L. Greene
Comprehensive analytical chemistry (2025)
Closed Access
Exploring Motivations, Experiences, and Consequences of Psychedelic Use in Aotearoa New Zealand
Ethan Mills, Jai Whelan, Sarah McGruddy, et al.
Journal of Psychoactive Drugs (2025), pp. 1-12
Open Access
An encounter with death: a comparative thematic and content analysis of naturalistic DMT experiences and the near-death experience
Pascal Michael, David Luke, Oliver Robinson
Frontiers in Psychology (2025) Vol. 16
Open Access
Liquid chromatography–tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma
Dino Luethi, Karolina E. Kolaczynska, Severin B. Vogt, et al.
Journal of Chromatography B (2022) Vol. 1213, pp. 123534-123534
Open Access | Times Cited: 18
Is there an affective neuroscience of spirituality? The development and validation of the OCEANic feelings scale
Beate Schmautz, Jürgen Fuchshuber, Deborah Andres, et al.
Frontiers in Human Neuroscience (2024) Vol. 18
Open Access | Times Cited: 3
Classic psychedelics do not affect T cell and monocyte immune responses
Deborah Rudin, Alexander Areesanan, Matthias E. Liechti, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 5
Application of Deuterated N,N-Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 9, pp. 1402-1404
Open Access | Times Cited: 8
Spectroscopic behavior of bufotenine and bufotenine N-oxide: Solvent and pH effects and interaction with biomembrane models
Gustavo Almeida e Silva, Vinícius Galvão Wakui, Lucília Kato, et al.
Biochimica et Biophysica Acta (BBA) - Biomembranes (2024) Vol. 1866, Iss. 4, pp. 184304-184304
Closed Access | Times Cited: 1
Application of microarray patches for the transdermal administration of psychedelics drugs in micro-doses
Octavio E. Fandiño, Aaron R.J. Hutton, Chunyang Zhang, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 207, pp. 114603-114603
Open Access | Times Cited: 1
The complete organellar genomes of the entheogenic plant Psychotria viridis (Rubiaceae), a main component of the ayahuasca brew
Alessandro M. Varani, Saura R. Silva, Simone Silva dos Santos Lopes, et al.
PeerJ (2022) Vol. 10, pp. e14114-e14114
Open Access | Times Cited: 5
Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis
Noah D. Gold, Austin Mallard, Jacob C. Hermann, et al.
Journal of Palliative Medicine (2023) Vol. 26, Iss. 10, pp. 1408-1418
Closed Access | Times Cited: 2
Visible-Light-Induced Metal-Free Selenation of Tryptamines/3-Substituted Indoles
Ravi P. Singh, Shashank Singh, Kalyan S. Naskar, et al.
Synthesis (2023) Vol. 55, Iss. 21, pp. 3685-3692
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top